Hindustan Laboratories, a Mumbai-based generic drug manufacturer, has filed draft documents with SEBI for an Initial Public Offering (IPO). The IPO aims to raise funds through a fresh issue of 50 lakh shares and an offer for sale of 91 lakh shares by its promoter. Proceeds will primarily fund working capital requirements and general corporate purposes. The company, established in 2017, supplies generic medicines to government institutions and has a diverse product portfolio across various therapeutic categories.